Activist Investing

The Accountability Board is pushing for an independent board chair, arguing that Brian Cornell’s planned transition to the role will hinder oversight of the retailer’s new CEO.

Activists also report to the SEC on LENZ Therapeutics and Opendoor Technologies.

Activists also report to the SEC on Life Time Group Holdings, V2X, and Opendoor Technologies.

Activist investor Elliott said Tuesday that it had built a stake of more than $2 billion in the HR software company.

Activists also report to the SEC on Acadian Asset Management, Cipher Mining, and Outfront Media

Activists also report to the SEC on Appian, GeneDX Holdings, and Stoke Therapeutics.

A recovery in Pepsi’s valuation could lift shares by more than 50%, one activist investor says.

The beverages and snacks maker has struggled in the face of stiff competition and macro uncertainty.

The state initiated a position in two European banks during the second quarter.

Activists also report to the SEC on BioLife Solutions, LENZ Therapeutics, and Garrett Motion.

Activists also report to the SEC on Appian, Garrett Motion, Arcellx, and Disc Medicine.

Activist investor Ancora has an idea that everyone else seems to share. It wants CSX to pursue a merger.

Software stocks get hammered, railroad CSX faces mounting pressure, Fed’s July meeting minutes are coming, and more news to start your day.

Medtronic appoints two new board directors following talks with activist investor Elliott Investment Management.

The Edge Consulting Group took a stake in Dine Brands and is pushing for change.

Activists also report to the SEC on Pacira BioSciences, Bristow Group, and Garrett Motion

Starboard Value buys more than 400,000 Salesforce shares in the second quarter.

Shares of the life-sciences company have plummeted due in part to reduced demand amid Trump administration cuts.

Activists also report to the SEC on Ermenegildo Zegna, RingCentral, and ARS Pharmaceuticals.

Activists also report to the SEC on Bitfarms, Zimvie,

Activists also report to the SEC on Bloom Energy, LENZ Therapeutics, and ARS Pharmaceuticals.

Activists also report to the SEC on Cogent Biosciences and Rocket Cos.

The stock has failed to recover from a big drop in April when the company bought rival Worldpay for $24 billion, which expanded Global Payments’ reach but created headaches in integrating the two businesses.

The company appoints longtime tech executive Robert M. Calderoni to the board as part of its agreement with activist investor Elliott.

Staboard Value and other investors disclose their positions in 13D filings with the SEC.